in preclinical and in-vitro systems it has been studied as a GHRH-receptor agonist on anterior pituitary cells, where it has been observed to stimulate the synthesis and pulsatile release of endogenous growth hormone
Clinical and member reports include: Studies outside Noom, including a 2,700-person Denmark trial, suggest users who stayed at microdose levels saw 16% body weight loss over 64 weeks, with minimized side effects (fatigue, GI upset) and improved cholesterol, markers of inflammation, and overall health. One user lost 25 pounds through Noom GLP 1 Cost support, reporting, Taking a GLP-1 significantly reduced my appetite, which meant I had to be intentional about getting enough nutrients
This analysis revealed that there was a small, but significant, reduction in subjective pain scores compared with placebo in patients experiencing acute pain [274]
it's a nationwide regulation
Pollock RF, Norrbacka K, Cameron C, Mancillas-Adame L, Jeddi M
Patients with hepatic steatosis, visceral adiposity, or reduced energy expenditure may particularly benefit from agents with GCGR activity (such as GLP-1/glucagon or triple GLP-1/GIP/glucagon agonists), which enhance lipid oxidation and thermogenesis
